Moxetumomab pasudotox is an anti-CD22 mouse monoclonal antibody designed for the treatment of cancer.Moxetumomab pasudotox is currently being developed by the biologics division of AstraZeneca MedImmune.On 16 May 2013 the first dose in a Phase III trail was administered.
This page contains content from the copyrighted Wikipedia article "Moxetumomab pasudotox"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.